Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative

M. Dougados, P. LeClaire, D. Van der Heijde, D. A. Bloch, N. Bellamy, Roy D Altman

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Background: The domains of pain, function and patient's global assessment are identified as core variables and frequently measured in clinical trials of patients with osteoarthritis (OA) of the hip and knee. Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient's global assessment. Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified response criteria which best discriminate active agent from placebo. Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of responder criteria are proposed: (1) 'high' pain response or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment; (2) 'high' response for either pain or function or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%. Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. (C) 2000 OsteoArthritis Research Society International.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalOsteoarthritis and Cartilage
Volume8
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Hip Osteoarthritis
Knee Osteoarthritis
Clinical Trials
Pain
Placebos
Drug products
Controlled Clinical Trials
Statistical methods
Osteoarthritis
Pharmaceutical Preparations
Oral Administration
Health
Consensus
Anti-Inflammatory Agents
Joints
Control Groups
Industry

Keywords

  • Clinical Trials Response Criteria Initiative

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Response criteria for clinical trials on osteoarthritis of the knee and hip : A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. / Dougados, M.; LeClaire, P.; Van der Heijde, D.; Bloch, D. A.; Bellamy, N.; Altman, Roy D.

In: Osteoarthritis and Cartilage, Vol. 8, No. 6, 2000, p. 395-403.

Research output: Contribution to journalArticle

@article{601465bb7eda4e98b123187abb94ada4,
title = "Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative",
abstract = "Background: The domains of pain, function and patient's global assessment are identified as core variables and frequently measured in clinical trials of patients with osteoarthritis (OA) of the hip and knee. Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient's global assessment. Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified response criteria which best discriminate active agent from placebo. Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of responder criteria are proposed: (1) 'high' pain response or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment; (2) 'high' response for either pain or function or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) ranged from 52 to 96{\%} and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73{\%}. Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. (C) 2000 OsteoArthritis Research Society International.",
keywords = "Clinical Trials Response Criteria Initiative",
author = "M. Dougados and P. LeClaire and {Van der Heijde}, D. and Bloch, {D. A.} and N. Bellamy and Altman, {Roy D}",
year = "2000",
doi = "10.1053/joca.2000.0361",
language = "English (US)",
volume = "8",
pages = "395--403",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Response criteria for clinical trials on osteoarthritis of the knee and hip

T2 - A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative

AU - Dougados, M.

AU - LeClaire, P.

AU - Van der Heijde, D.

AU - Bloch, D. A.

AU - Bellamy, N.

AU - Altman, Roy D

PY - 2000

Y1 - 2000

N2 - Background: The domains of pain, function and patient's global assessment are identified as core variables and frequently measured in clinical trials of patients with osteoarthritis (OA) of the hip and knee. Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient's global assessment. Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified response criteria which best discriminate active agent from placebo. Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of responder criteria are proposed: (1) 'high' pain response or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment; (2) 'high' response for either pain or function or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%. Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. (C) 2000 OsteoArthritis Research Society International.

AB - Background: The domains of pain, function and patient's global assessment are identified as core variables and frequently measured in clinical trials of patients with osteoarthritis (OA) of the hip and knee. Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient's global assessment. Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified response criteria which best discriminate active agent from placebo. Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of responder criteria are proposed: (1) 'high' pain response or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment; (2) 'high' response for either pain or function or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%. Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. (C) 2000 OsteoArthritis Research Society International.

KW - Clinical Trials Response Criteria Initiative

UR - http://www.scopus.com/inward/record.url?scp=0034528514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034528514&partnerID=8YFLogxK

U2 - 10.1053/joca.2000.0361

DO - 10.1053/joca.2000.0361

M3 - Article

C2 - 11069723

AN - SCOPUS:0034528514

VL - 8

SP - 395

EP - 403

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 6

ER -